UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Act of 1934
Date of Report (Date of earliest event reported) -September 27, 2004
IMCOR PHARMACEUTICAL CO.
(Exact name as specified in its charter)
NEVADA | 0-23553 | 62-1742885 |
|
|
|
(State or other jurisdiction of Incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) |
6175 Lusk Boulevard | |
San Diego, CA | 92121 |
|
|
(Address of principal executive offices) | (Zip Code) |
(858) 410-5601
(Registrants' telephone number, including area code)
Photogen Technologies, Inc.
(Former name or former address, if changed since last report)
On September, 27, 2004, IMCOR Pharmaceutical Co. (the “Company”) issued a press release announcing that Brooks Boveroux will leave his position as chief financial officer of the Company. Until a successor is appointed, Taffy Williams will be the acting chief financial officer. Dr. Williams will be assisted by Larry Grant, a consultant who is a certified public accountant and who has 30 years of experience in providing accounting and financial services, and the Company’s existing staff.
| Item 9.01. | | FINANCIAL STATEMENTS AND EXHIBITS. |
| | | |
(c) | | Exhibits. The following exhibits are filed with this report: |
| | | |
| | | Exhibit 99.1 - Press Release of the Company, dated September 27, 2004. |
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed by the undersigned hereunto duly authorized.
| | | |
| | IMCOR Pharmaceutical Co. |
|
|
|
| By: | /s/ Taffy J. Williams |
| |
|
| | Taffy J. Williams, Ph.D. President and Chief Executive Officer |
Dated: September 27, 2004
EXHIBIT INDEX
| Exhibit No. | Description |
| | |
| Exhibit 99.1 | Press Release of the Company, dated September 27, 2004. |
